CytomX Therapeutics Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street’s Most Accurate Analysts

All NewsMarch 16, 2026

CytomX Therapeutics (CTMX) will release its Q4 earnings on March 16, with analysts expecting a loss of 9 cents per share. Stock fell 3.9% on Friday.

Latest Ratings for CTMX

DateFirmActionFromTo Mar 2022JP MorganMaintainsOverweight Jan 2022BarclaysUpgradesUnderweightOverweight Dec 2021HC Wainwright & Co.MaintainsBuy

View More Analyst Ratings for CTMX

View the Latest Analyst Ratings

Importance Rank:

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Manage consent